NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee B meeting minutes

**Minutes:** Confirmed

**Date:** Wednesday 2nd July

**Location:** Via Zoom and London Office

## Attendees

Committee members present

1. Dr Charles Crawley (Chair) Present for all items
2. Baljit Singh (Vice-chair) Present for all items
3. Vanessa Danielson Present for all items
4. Dr Daniel Gallacher Present for all items
5. Dr Bushra Hasnie Present for all items
6. Dr Warren Linley Present for all items
7. Dr Andrew Makin Present for all items
8. Professor David McAllister Present for all items
9. Stella O’Brien Present for all items
10. Anna Pracz Present for all items
11. Gabriel Rogers Present for all items
12. Soon Song Present for all items
13. Dr Toby Smith Present for all items
14. Nigel Westwood Present for all items
15. Peter Wheatley-Price Items 5.1 to 5.2.2
16. Tony Wootton Present for all items

NICE staff (key players) present

Richard Diaz, Associate Director Present for all items

Thomas Feist, Project Manager Present for all items

Christian Griffiths, Heath Technology Assessment Adviser Items 1.1 to 4.2.2

Alice Pritchard, Heath Technology Assessment Analyst Items 1.1 to 4.2.2

Nigel Gumbleton, Heath Technology Assessment Analyst Items 5.1 to 5.2.2

Emilene Coventry, Administrator, Technology Appraisals Items 5.1 to 5.2.2

External assessment group representatives present

Janette Greenhalgh, Liverpool Reviews and Implementation Group

Items 1.1 to 4.1.3

James Mahon, Liverpool Reviews and Implementation Group

Items 1.1 to 4.1.3

Kate Ennis, BMJ Technology Assessment Group Items 5.1 to 5.1.3

Clare Dadswell, BMJ Technology Assessment Group Items 5.1 to 5.1.3

Clinical, Patient & NHS England experts present

Jaimal Kothari, Clinical expert, Consultant Haematologist nominated by Sanofi

Items 1.1 to 4.1.3

Neil Rabin, Clinical expert, Consultant Haematologist nominated by UK Myeloma Society

Frankie McGauran, Patient expert, nominated by Myeloma UK

Items 1.1 to 4.1.3

Caroline Donoghue, National Cancer Drugs Fund Clinical Lead

Items 1.1 to 4.1.3

Claire Hopkins, Clinical expert, Professor of Rhinology nominated by Sanofi

Items 5.1 to 5.1.3

Carl Philpot, Clinical expert, Professor of Rhinology & Olfactology nominated by Sanofi and Fifth Sense (Trustee of Fifth Sense) Items 5.1 to 5.1.3

Andrew Knill, Patient expert, nominated by Sinus UK (Chief Executive)

Items 5.1 to 5.1.3

Sophie Dodworth, Patient expert, nominated by Fifth Sense Items 5.1 to 5.1.3

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Alistair Patton, Francis Drobniewski, Kemi Gibson, Lisa Attrill, Mariana Bacelar, Rhiannon Owen, Sunita Sharma, Veline L’Esperance and Hatim Abdulhussein.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Wednesday 4th June.

1. **Appraisal of Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable [ID3981]**
   1. Part 1 – Open session
      1. The chair, Charles Crawley, welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Sanofi.
      2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10912).
      3. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by Charles Crawley.
   2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
      1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
      2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.

* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10912>.

1. **Appraisal of Dupilumab for treating severe chronic rhinosinusitis with nasal polyposis (Review of TA648) [ID6480]** 
   1. Part 1 – Open session
      1. The chair, Baljit Singh, welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Sanofi.
      2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11630).
      3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Tony Wootton (lay), Andrew Makin (clinical) and Gabriel Rogers (cost).
   2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
      1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
      2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.

* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11630>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee B will be held on Wednesday 6th August and will start promptly at 9am.